← Oncology Approval Tracker

FDA DECISION ·

Keytruda or Keytruda Qlex + Padcev

pembrolizumab (IV or with berahyaluronidase alfa-pmph SC) + enfortumab vedotin-ejfv · Merck and Astellas Pharma

FDA approvalNew or expanded indicationMuscle-invasive bladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With either pembrolizumab formulation and enfortumab vedotin-ejfv before cystectomy and as adjuvant therapy afterward for adults with muscle-invasive bladder cancer who are ineligible for cisplatin.

LAMPGEN ANALYSIS

Why it matters

This decision added a perioperative checkpoint inhibitor and antibody–drug conjugate regimen for cisplatin-ineligible patients.

What research teams should watch

Capture the basis for cisplatin ineligibility, protect the surgery window, and assign responsibility for rash and neuropathy monitoring.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Perioperative muscle-invasive bladder cancer

PRIMARY RECORDS

Sources